Last reviewed · How we verify
Zirconium Zr 89-Df-Crefmirlimab
At a glance
| Generic name | Zirconium Zr 89-Df-Crefmirlimab |
|---|---|
| Also known as | 89Zr-Crefmirlimab Berdoxam, 89Zr-Desferrioxamine-IAB22M2C, 89Zr-Df-Crefmirlimab, 89Zr-Df-IAB22M2C, Zirconium Zr 89-Df-IAB22M2C |
| Sponsor | City of Hope Medical Center |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- CD8 PET Imaging in Metastatic Solid Tumours (PHASE2)
- Zr-89 Crefmirlimab Berdoxam and Immuno-Positron Emission Tomography for the Imaging of Patients With Resectable Brain Tumors (PHASE1)
- Study to Evaluate CD8 PET Imaging as a Marker of Immune Response to Stereotactic Body Radiation Therapy (ELIXR) (PHASE1)
- Zr89 + PET Companion Trial (EARLY_PHASE1)
- A Study of CD8+ T Cell Imaging During Treatment in People With Non-Small Cell Lung Cancer (PHASE1)
- CD8 Minibody Repeatability Study (PHASE2)
- Study of Zirconium Zr 89 Crefmirlimab Berdoxam PET/CT in Subjects With Advanced or Metastatic Malignancies (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Zirconium Zr 89-Df-Crefmirlimab CI brief — competitive landscape report
- Zirconium Zr 89-Df-Crefmirlimab updates RSS · CI watch RSS
- City of Hope Medical Center portfolio CI